Trade Names:
Synonyms:
Status: Approved (2008)
Entry Type: Small molecule
Molecule Category: Parent Prodrug
ATC: D07AC19
UNII: S8A06QG2QE

Structure

InChI Key WYQPLTPSGFELIB-JTQPXKBDSA-N
Smile CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI
InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C27H34F2O7
Molecular Weight 508.56
AlogP 3.52
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 6.0
Polar Surface Area 106.97
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 36.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist PubMed
Primary Target
Glucocorticoid receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Uveitis, Anterior 4 D014606 ClinicalTrials
Inflammation 4 D007249 ClinicalTrials
Uveitis 3 D014605 ClinicalTrials
Cataract 3 D002386 ClinicalTrials
Panuveitis 3 D015864 ClinicalTrials
Dry Eye Syndromes 2 D015352 ClinicalTrials

Related Entries

Scaffolds

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
28.41
Investigations
21.95
General disorders and administration site conditions
10.81
Nervous system disorders
9.38
Injury, poisoning and procedural complications
6.01
Skin and subcutaneous tissue disorders
5.07
Immune system disorders
3.14
Respiratory, thoracic and mediastinal disorders
2.32
Product issues
2.15
Vascular disorders
2.1

Cross References

Resources Reference
CAS NUMBER 23674-86-4
ChEBI 31485
ChEMBL CHEMBL1201749
DrugBank DB06781
DrugCentral 3142
EPA CompTox DTXSID0046773
FDA SRS S8A06QG2QE
Human Metabolome Database HMDB0061149
Guide to Pharmacology 7474
KEGG C12695
PharmGKB PA165958405
PubChem 443936
SureChEMBL SCHEMBL4580
ZINC ZINC000004212945